Flare Therapeutics Presents Part A Data from FX-909 Phase 1 Study at AACR-NCI-EORTC International Conference
October 24, 2025 12:00 ET | Source: Flare Therapeutics Inc. FX-909, the…
Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors
– QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and…
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
October 24, 2025 11:39 ET | Source: PMV Pharmaceuticals, Inc. Data presented…
Shanghai Electric Signs Parau Phase II 342 MW PV Project with Econergy, Supporting Romania’s Green Future
As Shanghai Electric's fourth photovoltaic project in Romania, this initiative marks a…
DXC Appoints Anthony Pappas as Chief Marketing Officer to Lead Next Phase of Brand Transformation
ASHBURN, Va., Oct. 23, 2025 /PRNewswire/ -- DXC Technology (NYSE: DXC), a…
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjgrens Disease
October 22, 2025 16:30 ET | Source: Vor Biopharma CAMBRIDGE, Mass., Oct.…
PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint…
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Long-term continuous OGSIVEO treatment for up to 4 years was associated with…
IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
October 20, 2025 02:30 ET | Source: IO Biotech Cylembio plus pembrolizumab…
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha…
